FDAnews Drug Daily Bulletin

CORAM, INC. TO PROVIDE VIVAGLOBIN, NEW SUBCUTANEOUS IMMUNOGLOBULIN

April 17, 2006
A A

Coram, Inc., a leading provider of home infusion and specialty pharmaceutical distribution services, announced today that it has been selected by ZLB Behring as a national provider of Vivaglobin (Immune Globulin Subcutaneous (Human)). Vivaglobin recently became the first and only U.S. Food and Drug Administration-approved subcutaneous (SC) immunoglobulin (Ig) treatment and can be safely self-administered by primary immunodeficiency (PI) patients under a physician's care in the United States.
PrimeZone